Bengaluru: Genetic diagnostic and drug discovery analysis firm MedGeneome Labs on Thursday claimed to have developed the primary complete genomic sequencing-based test to detect early drug-resistant mutation in tuberculosis (TB) micro organism.
“The breakthrough DNA test will enable a doctor to correctly prescribe the most effective drug to a TB patient without a time-consuming trial and error process,” stated the city-based medical data-driven Labs.
Announcing its foray into infectious illness testing in TB, central nervous system (CNS), systemic and eye infections, the corporate stated India had the biggest variety of multi-drug resistant (MDR) TB circumstances.
“India has the largest number of MDR-TB cases. Our spit sequence can be a boon for TB patients, clinicians and healthcare agencies to achieve the sustainable development goal of eliminating TB by 2025,” Labs Chief Operating Officer V.L. Ramprasad instructed reporters right here.
The central Health and Family Welfare ministry has estimated round 21 lakh individuals being affected by the dreaded infectious illness throughout the nation in 2018.
“The test is based on the whole genome sequencing of mycobacterium tuberculosis (MTB), the TB causing bacteria, to assess the mutations in bacteria’s genome and allows a clinician to determine which drug will work for a patient,” he stated.
There are 14 sorts of medicine for treating TB micro organism of assorted hues if detected early.
Mumbai-based P.D. Hinduja Hospital and Medical Research Centre head Camilla Rodrigues stated the test was validated with 100 samples recording 100 per cent sensitivity and 98.04 per cent specificity in contrast with line probe assay know-how.
“Of the 100 samples, 50 were tested in our hospital. The findings in the manuscript are under review for publication,” Rodrigues stated on the event by way of video-conference from Mumbai.
A noting that the method of analyzing the drug resistance was lengthy, which is delaying early therapy for MDR-TB affected person, Rodrigues stated the present experience allowed testing resistance solely on four medicine, which makes the affected person wait till testing on all attainable medicine concluded.
“Direct whole genome sequencing reveals information on drug resistance mutations for all anti-TB drugs in 10 days. Our testing will help to optimise the management of an MDR-TB patient”, she added.
The value for the TB affected person will Rs 7,800 per test.
According to the World Health Organisation (WHO) report, there have been 27 lakh TB circumstances (incidence + relapse) in 2017 and India accounted for 27 per cent of worldwide TB deaths.
Second appalling perception is globally, 3.5 per cent of the brand new TB circumstances and 18 per cent of beforehand handled sufferers suffered from relapse due to the immunity developed by TB micro organism.
“The conventional tests available in the country equip us to identify resistance in a limited fashion. Mtb (Mycobacterium tuberculosis) is slow-growing, taking 6-8 weeks for culture growth, thereby delaying not only TB diagnosis, but also the drug resistance testing,” stated the Labs in an announcement.
Spit sequence is a culture-free technique to determine Mtb and predict drug resistance in 10 days.
“Spit sequence is a breakthrough that can help millions. The test brings accurate results and saves time for early treatment,” added Ramprasad.
With the flagship test for tuberculosis, Labs will collaborate with XCyton Diagnostics on this tech hub to conduct varied genetic checks for eye, mind and blood infections.
MedGenome would be the gross sales accomplice for all XCyton checks in India.
“As infectious diseases remain a challenge, leading to significant healthcare expenditure, our partnership can act as a synergy in the country’s quest against them,” stated XCyton Diagnostics Ltd founder-managing director B.V. Ravikumar.